All Oncology News

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Sara A. Hurvitz, MD, discusses de-escalation strategies in early-stage HER2-positive breast cancer and novel HER2-targeted therapies in development.

Lee S. Rosen, MD, FACP, discusses the benefits of bevacizumab and how biosimilars could change the field.

A new drug application has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.

Abhinav Deol, MD, discusses the presentation and prevalence of idiopathic thrombocytopenic purpura in addition to the current and emerging therapeutic strategies that are used to manage the disease.

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

Josephine L. Feliciano, MD, discusses established and emerging therapeutic developments for patients with non–small cell lung cancer with less common driver mutations.

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.

Dennis J. Slamon, MD, PhD, discusses how the MONALEESA-3 results have shifted the understanding of therapy placement in women with HR-positive, HER2-negative advanced breast cancer.

Deepu Madduri, MD, discusses the role of CAR T-cell therapy and other novel treatment options for patients with relapsed/refractory multiple myeloma.

Researchers are exploring combination approaches with ruxolitinib (Jakafi) in myelofibrosis as a potential strategy for reinvigorating the drug’s effect in patients who progress, relapse, or become intolerant on single-agent treatment with the JAK inhibitor.

Fred Saad, MD, discusses the clinical significance of the SPARTAN trial, the HRQoL data, and remaining steps in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Adam F. Brufsky, MD, PhD, discusses the differences between biosimilars and biologics, incentives for biosimilar use, and investigational agents on the horizon.

The pipeline for relapsed/refractory mantle cell lymphoma treatment is beginning to evolve with novel agents and combination regimens that have the potential to improve patient outcomes.

Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.

Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma.

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Cure rates in diffuse large B-cell lymphoma remain relatively unchanged, even following therapeutic additions to the armamentarium and an improved understanding of disease biology.

Hundreds of oncology professionals will gather for this “how-to” conference to hear innovative strategies for enhancing program operations, addressing gaps in care delivery, tackling real-world challenges, and supporting a culture of well-being for the entire multidisciplinary care team.

Phase I data showed that combining venetoclax and navitoclax plus chemotherapy demonstrated encouraging responses and tolerability in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma.

While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.

Early identification of inherited predisposition to forms of myelodysplastic syndrome and acute myeloid leukemia in pediatric patients can assist in treatment decisions and selection for familial stem cell transplant.

The FDA has approved moxetumomab pasudotox for the treatment of adult patients with relapsed or refractory hairy cell leukemia following at least 2 prior lines of therapy.

Julio C. Chavez, MD, discusses prognostic indicators and systemic treatment updates for patients with acute lymphoblastic leukemia.

Bradley McGregor, MD, discusses the impact of combination therapies on the treatment landscape and highly anticipated studies in renal cell carcinoma.

Following survival improvements in the field of adolescents and young adults with acute lymphoblastic leukemia, researchers must turn their focus to lowering toxicity, and delivering treatment to high-risk subgroups, among others.

Kenneth H. Shain, MD, PhD, discusses the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with chimeric antigen receptor T-cell therapy and minimal residual disease negativity to improve outcomes.

Philip Bierman, MD, discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that should be conducted.

Frederick L. Locke, MD, discusses the expansion of CAR T-cell therapy in patients with lymphomas following the 2017 approval of axicabtagene ciloleucel and remaining research questions with the therapy.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for October 10, 2018, to discuss a biologics license application for CT-P10, a proposed biosimilar to rituximab.